A Vaginal Ring Containing Dapivirine for HIV-1 PrEP

Ring
A Vaginal Ring Containing Dapivirine for HIV-1 PrEP

Ring Study: Background

**Study Design: Ring**

- **Background**: Randomized, double-blind, phase 3, placebo-controlled trial of a dapivirine-containing vaginal ring changed every 4 weeks as compared to a placebo ring for HIV-1 prevention for women at multiple sites in 7 communities in South Africa and Uganda.
  - Inclusion Criteria (1,959 enrolled)
    - 18-45 years of age
    - HIV seronegative
    - Sexually active
    - Nonpregnant and on stable contraceptive
  - Treatment Arms:
    - Dapivirine 25 mg vaginal ring, changed monthly
    - Placebo vaginal ring, changed monthly

A Vaginal Ring Containing Dapivirine for HIV-1 PrEP Ring Study: Results

Incidence Rate for New HIV Infections

A Vaginal Ring Containing Dapivirine for HIV-1 PrEP Ring Study: Results

Relative Reduction, by Age Group

Conclusions: “Among women in sub-Saharan Africa, the dapivirine ring was not associated with any safety concerns and was associated with a rate of acquisition of HIV-1 infection that was lower than the rate with placebo.”

Acknowledgment

The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program resource funded by the United States Health Resources and Services Administration. The project is led by the University of Washington and the AETC National Coordinating Resource Center.

*The content in this slide set does not represent the official views of the U.S. Department of Health and Human Services, Health Resources & Services Administration.*